Alkem Laboratories Ltd
NSE:ALKEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (30.7), the stock would be worth ₹4 647.91 (14% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 35.7 | ₹5 400 |
0%
|
| 3-Year Average | 30.7 | ₹4 647.91 |
-14%
|
| 5-Year Average | 31.7 | ₹4 796.73 |
-11%
|
| Industry Average | 29.2 | ₹4 409.24 |
-18%
|
| Country Average | 23 | ₹3 470.74 |
-36%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Alkem Laboratories Ltd
NSE:ALKEM
|
639B INR | 35.7 | 27.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 52.5 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 22.6 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 19.7 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 16.4 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 14.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.1 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 13 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 8.6 | 17.3 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 14 |
| Median | 23 |
| 70th Percentile | 39.7 |
| Max | 28 676 |
Other Multiples
Alkem Laboratories Ltd
Glance View
Alkem Laboratories Ltd., founded in 1973, has emerged as a significant player in India's pharmaceutical landscape, deftly combining innovation with a robust distribution network. Anchored in Mumbai, Alkem began as a modest venture but quickly evolved into a powerhouse, renowned for manufacturing a broad spectrum of branded generics, over-the-counter products, and active pharmaceutical ingredients (APIs). The company's success lies in its ability to cater to both domestic and international markets, primarily thriving on the ever-increasing demand for affordable healthcare solutions. Its formidable market presence in India is supported by a strong sales force and an extensive distribution network, ensuring its therapies reach even the most remote corners of the country. Internationally, Alkem has carved a niche for itself, with the United States being one of its major export markets. It strategically entered this competitive arena, building a portfolio of ANDAs (Abbreviated New Drug Applications) that allowed it to provide lower-cost alternatives to big pharma's patented drugs. This not only fueled its revenue growth but also fortified its standing as a go-to source for quality generics. Alkem's research and development efforts underpin its commitment to healthcare innovation, as it constantly seeks to expand its therapeutic repertoire. By consistently focusing on quality, affordability, and resourceful adaptation to global healthcare needs, Alkem Laboratories Ltd. has managed to script a growth story that is both impressive and sustainable.